Honing Biosciences
Paris
About Honing Biosciences
Honing Biosciences is a bio-therapeutics company that develops and improves cell-based therapies in particular of cancer and other chronic diseases. Cell-based approaches represent a promising avenue to develop novel therapies. Honing Biosciences leverages technologies that allow precise control of cell functions after delivery to patients, increasing the efficacy and limiting the harmful drawbacks of previous generations of treatments. Our molecular CellTuneTM technology allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. We can thus regulate protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences proprietary technological platform has breakthrough applications all types of cell-based therapy, including immunotherapy and reconstituting cell therapies for autoimmunity and chronic diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.3M
- Funding stage: Seed
- Last round: Pre-Seed (Jul 2020)
- Website: honing-biosciences.com
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/honing-biosciences-147094 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.